Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02482454 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | active not recruiting | Phase 2 / Phase 3 | 50 | The First People's Hospital of ChangzhouOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT03047265 | Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 164 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2017 |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02490748 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer | active not recruiting | Phase 2 | 10 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02491697 | Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02493582 | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 5, 2016 | clinicaltrials |
| NCT02259556 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas(CART30) | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02497898 | Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 1,000 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 15, 2015 | clinicaltrials |
| NCT02498756 | Cytokine-induced Killer Study for Patients With Stage II Melanoma | not yet recruiting | Phase 2 | 300 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 15, 2015 | clinicaltrials |
| NCT02490735 | CIK in Treating Patients With Esophageal Cancer | not yet recruiting | Phase 2 | 2,000 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 7, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2017source: clinicaltrials